Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 118(28)2021 07 13.
Article in English | MEDLINE | ID: mdl-34260394

ABSTRACT

The evolutionary expansion of G protein-coupled receptors (GPCRs) has produced a rich diversity of transmembrane sensors for many physical and chemical signals. In humans alone, over 800 GPCRs detect stimuli such as light, hormones, and metabolites to guide cellular decision-making primarily using intracellular G protein signaling networks. This diversity is further enriched by GPCRs that function as molecular sensors capable of discerning multiple inputs to transduce cues encoded in complex, context-dependent signals. Here, we show that many GPCRs are coincidence detectors that couple proton (H+) binding to GPCR signaling. Using a panel of 28 receptors covering 280 individual GPCR-Gα coupling combinations, we show that H+ gating both positively and negatively modulates GPCR signaling. Notably, these observations extend to all modes of GPCR pharmacology including ligand efficacy, potency, and cooperativity. Additionally, we show that GPCR antagonism and constitutive activity are regulated by H+ gating and report the discovery of an acid sensor, the adenosine A2a receptor, which can be activated solely by acidic pH. Together, these findings establish a paradigm for GPCR signaling, biology, and pharmacology applicable to acidified microenvironments such as endosomes, synapses, tumors, and ischemic vasculature.


Subject(s)
Protons , Receptors, G-Protein-Coupled/metabolism , Signal Transduction , HEK293 Cells , Humans , Hydrogen-Ion Concentration , Models, Biological , Receptors, G-Protein-Coupled/agonists , Reproducibility of Results , Saccharomyces cerevisiae/metabolism
2.
J Biol Chem ; 296: 100167, 2021.
Article in English | MEDLINE | ID: mdl-33478938

ABSTRACT

Of the 800 G protein-coupled receptors (GPCRs) in humans, only three (GPR4, GPR65, and GPR68) regulate signaling in acidified microenvironments by sensing protons (H+). How these receptors have uniquely obtained this ability is unknown. Here, we show these receptors evolved the capability to sense H+ signals by acquiring buried acidic residues. Using our informatics platform pHinder, we identified a triad of buried acidic residues shared by all three receptors, a feature distinct from all other human GPCRs. Phylogenetic analysis shows the triad emerged in GPR65, the immediate ancestor of GPR4 and GPR68. To understand the evolutionary and mechanistic importance of these triad residues, we developed deep variant profiling, a yeast-based technology that utilizes high-throughput CRISPR to build and profile large libraries of GPCR variants. Using deep variant profiling and GPCR assays in HEK293 cells, we assessed the pH-sensing contributions of each triad residue in all three receptors. As predicted by our calculations, most triad mutations had profound effects consistent with direct regulation of receptor pH sensing. In addition, we found that an allosteric modulator of many class A GPCRs, Na+, synergistically regulated pH sensing by maintaining the pKa values of triad residues within the physiologically relevant pH range. As such, we show that all three receptors function as coincidence detectors of H+ and Na+. Taken together, these findings elucidate the molecular evolution and long-sought mechanism of GPR4, GPR65, and GPR68 pH sensing and provide pH-insensitive variants that should be valuable for assessing the therapeutic potential and (patho)physiological importance of GPCR pH sensing.


Subject(s)
Protons , Receptors, G-Protein-Coupled/metabolism , Sodium/metabolism , Allosteric Regulation , Amino Acid Substitution , Binding Sites , Cations, Monovalent , Computational Biology/methods , Evolution, Molecular , Gene Expression , HEK293 Cells , Humans , Hydrogen-Ion Concentration , Models, Molecular , Mutation , Phylogeny , Protein Binding , Protein Conformation, alpha-Helical , Receptors, G-Protein-Coupled/chemistry , Receptors, G-Protein-Coupled/genetics , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Sodium/chemistry
3.
J Biol Chem ; 295(24): 8262-8271, 2020 06 12.
Article in English | MEDLINE | ID: mdl-32358068

ABSTRACT

Genome stability is essential for engineering cell-based devices and reporter systems. With the advent of CRISPR technology, it is now possible to build such systems by installing the necessary genetic parts directly into an organism's genome. Here, we used this approach to build a set of 10 versatile yeast-based reporter strains for studying human G protein-coupled receptors (GPCRs), the largest class of membrane receptors in humans. These reporter strains contain the necessary genetically encoded parts for studying human GPCR signaling in yeast, as well as four CRISPR-addressable expression cassettes, i.e. landing pads, installed at known safe-harbor sites in the yeast genome. We showcase the utility of these strains in two applications. First, we demonstrate that increasing GPCR expression by incrementally increasing GPCR gene copy number potentiates Gα coupling of the pharmacologically dark receptor GPR68. Second, we used two CRISPR-addressable landing pads for autocrine activation of a GPCR (the somatostatin receptor SSTR5) with its peptide agonist SRIF-14. The utility of these reporter strains can be extended far beyond these select examples to include applications such as nanobody development, mutational analysis, drug discovery, and studies of GPCR chaperoning. Additionally, we present a BY4741 yeast strain created for broad applications in the yeast and synthetic biology communities that contains only the four CRISPR-addressable landing pads. The general utility of these yeast strains provides an inexpensive, scalable, and easy means of installing and expressing genes directly from the yeast genome to build genome-barcoded sensors, reporter systems, and cell-based factories.


Subject(s)
Clustered Regularly Interspaced Short Palindromic Repeats/genetics , Receptors, G-Protein-Coupled/metabolism , Saccharomyces cerevisiae/metabolism , Synthetic Biology , Autocrine Communication , Gene Dosage , Genes, Reporter , Humans , Metabolic Engineering , Pheromones/metabolism , Receptors, Mating Factor/metabolism , Receptors, Somatostatin/metabolism , Reproducibility of Results , Saccharomyces cerevisiae Proteins/metabolism , Signal Transduction , Somatostatin/analogs & derivatives , Somatostatin/pharmacology
4.
Front Cell Dev Biol ; 8: 603688, 2020.
Article in English | MEDLINE | ID: mdl-33409279

ABSTRACT

Arginyltransferase 1 (ATE1) is an evolutionary-conserved eukaryotic protein that localizes to the cytosol and nucleus. It is the only known enzyme in metazoans and fungi that catalyzes posttranslational arginylation. Lack of arginylation has been linked to an array of human disorders, including cancer, by altering the response to stress and the regulation of metabolism and apoptosis. Although mitochondria play relevant roles in these processes in health and disease, a causal relationship between ATE1 activity and mitochondrial biology has yet to be established. Here, we report a phylogenetic analysis that traces the roots of ATE1 to alpha-proteobacteria, the mitochondrion microbial ancestor. We then demonstrate that a small fraction of ATE1 localizes within mitochondria. Furthermore, the absence of ATE1 influences the levels, organization, and function of respiratory chain complexes in mouse cells. Specifically, ATE1-KO mouse embryonic fibroblasts have increased levels of respiratory supercomplexes I+III2+IVn. However, they have decreased mitochondrial respiration owing to severely lowered complex II levels, which leads to accumulation of succinate and downstream metabolic effects. Taken together, our findings establish a novel pathway for mitochondrial function regulation that might explain ATE1-dependent effects in various disease conditions, including cancer and aging, in which metabolic shifts are part of the pathogenic or deleterious underlying mechanism.

5.
Oncogene ; 38(6): 838-851, 2019 02.
Article in English | MEDLINE | ID: mdl-30177837

ABSTRACT

Most prostate cancer cases remain indolent for long periods of time, but metastatic progression quickly worsens the prognosis and leads to mortality. However, little is known about what promotes the metastasis of prostate cancer and there is a lack of effective prognostic indicators, making it immensely difficult to manage options for treatment or surveillance. Arginyltransferase 1 (Ate1) is the enzyme mediating post-translational protein arginylation, which has recently been identified as a master regulator affecting many cancer-relevant pathways including stress response, cell cycle checkpoints, and cell migration/adhesion. However, the precise role of Ate1 in cancer remains unknown. In this study, we found the occurrence of metastasis of prostate cancer is inversely correlated with the levels of Ate1 protein and mRNA in the primary tumor. We also found that metastatic prostate cancer cell lines have a reduced level of Ate1 protein compared to non-metastatic cell lines, and that a depletion of Ate1 drives prostate cancer cells towards more aggressive pro-metastatic phenotypes without affecting proliferation rates. Furthermore, we demonstrated that a reduction of Ate1 can result from chronic stress, and that shRNA-reduced Ate1 increases cellular resistance to stress, and drives spontaneous and stress-induced genomic mutations. Finally, by using a prostate orthotropic xenograft mouse model, we found that a reduction of Ate1 was sufficient to enhance the metastatic phenotypes of prostate cancer cell line PC-3 in vivo. Our study revealed a novel role of Ate1 in suppressing prostate cancer metastasis, which has a profound significance for establishing metastatic indicators for prostate cancer, and for finding potential treatments to prevent its metastasis.


Subject(s)
Aminoacyltransferases/metabolism , Cell Movement , Neoplasm Proteins/metabolism , Prostatic Neoplasms/enzymology , Prostatic Neoplasms/metabolism , Aminoacyltransferases/genetics , Animals , HEK293 Cells , Humans , Male , Mice , Mice, Knockout , Neoplasm Metastasis , Neoplasm Proteins/genetics , Prognosis , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/pathology
6.
Cell Death Dis ; 7(9): e2378, 2016 09 29.
Article in English | MEDLINE | ID: mdl-27685622

ABSTRACT

Arginyltransferase 1 (Ate1) mediates protein arginylation, a poorly understood protein posttranslational modification (PTM) in eukaryotic cells. Previous evidence suggest a potential involvement of arginylation in stress response and this PTM was traditionally considered anti-apoptotic based on the studies of individual substrates. However, here we found that arginylation promotes cell death and/or growth arrest, depending on the nature and intensity of the stressing factor. Specifically, in yeast, mouse and human cells, deletion or downregulation of the ATE1 gene disrupts typical stress responses by bypassing growth arrest and suppressing cell death events in the presence of disease-related stressing factors, including oxidative, heat, and osmotic stresses, as well as the exposure to heavy metals or radiation. Conversely, in wild-type cells responding to stress, there is an increase of cellular Ate1 protein level and arginylation activity. Furthermore, the increase of Ate1 protein directly promotes cell death in a manner dependent on its arginylation activity. Finally, we found Ate1 to be required to suppress mutation frequency in yeast and mammalian cells during DNA-damaging conditions such as ultraviolet irradiation. Our study clarifies the role of Ate1/arginylation in stress response and provides a new mechanism to explain the link between Ate1 and a variety of diseases including cancer. This is also the first example that the modulation of the global level of a PTM is capable of affecting DNA mutagenesis.


Subject(s)
Aminoacyltransferases/metabolism , Arginine/metabolism , DNA/metabolism , Mutagenesis/genetics , Protein Processing, Post-Translational , Saccharomyces cerevisiae Proteins/metabolism , Stress, Physiological , Animals , Base Sequence , Cell Death , Cell Survival/radiation effects , DNA Damage , Down-Regulation , Embryo, Mammalian/cytology , Fibroblasts/metabolism , Gene Knockdown Techniques , Mice , Saccharomyces cerevisiae/enzymology , Saccharomyces cerevisiae/genetics , Ultraviolet Rays , Up-Regulation
7.
J Strength Cond Res ; 27(1): 166-73, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22395264

ABSTRACT

This study aimed to quantify the influence of neuromuscular fatigue (NMF) via flight time to contraction time ratio (FT:CT) obtained from a countermovement jump (CMJ) on the relationships between yo-yo intermittent recovery (level 2) test (yo-yo IR2), match exercise intensity (high-intensity running [HIR] m·min(-1) and Load·min(-1)) and Australian football (AF) performance. Thirty-seven data sets were collected from 17 different players across 22 elite AF matches. Each data set comprised an athlete's yo-yo IR2 score before the start of the season, match exercise intensity via global positioning system and on-field performance rated by coaches' votes and number of ball disposals. Each data set was categorized as normal (>92% baseline FT:CT, n = 20) or fatigued (<92% baseline FT:CT, n = 17) from a single CMJ performed 96 hours after the previous match. Moderation-mediation analysis was completed with yo-yo IR2 (independent variable), match exercise intensity (mediator), and AF performance (dependent variable) with NMF status as the conditional variable. Isolated interactions between variables were analyzed by Pearson's correlation and effect size statistics. The Yo-yo IR2 score showed an indirect influence on the number of ball disposals via HIR m·min(-1) regardless of NMF status (normal FT:CT indirect effect = 0.019, p < 0.1, reduced FT:CT indirect effect = 0.022, p < 0.1). However, the yo-yo IR2 score only influenced coaches' votes via Load·min(-1) in the nonfatigued state (normal: FT:CT indirect effect = 0.007, p <0.1, reduced: FT:CT indirect effect = -0.001, p > 0.1). In isolation, NMF status also reduces relationships between yo-yo IR2 and load·min(-1), yo-yo IR2 and coaches votes, Load·min(-1) and coaches' votes (Δr > 0.1). Routinely testing yo-yo IR2 capacity, NMF via FT:CT and monitoring Load·min(-1) in conjunction with HIR m·min(-1) as exercise intensity measures in elite AF is recommended.


Subject(s)
Athletic Performance/physiology , Competitive Behavior , Football/physiology , Muscle Fatigue/physiology , Physical Endurance/physiology , Humans , Longitudinal Studies , Male , Prospective Studies , Running/physiology , Young Adult
8.
PLoS Negl Trop Dis ; 5(12): e1425, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22163059

ABSTRACT

P-glycoprotein (Pgp) and multidrug resistance-associated proteins (MRPs) are ATP-dependent transporters involved in efflux of toxins and xenobiotics from cells. When overexpressed, these transporters can mediate multidrug resistance (MDR) in mammalian cells, and changes in Pgp expression and sequence are associated with drug resistance in helminths. In addition to the role they play in drug efflux, MDR transporters are essential components of normal cellular physiology, and targeting them may prove a useful strategy for development of new therapeutics or of compounds that enhance the efficacy of current anthelmintics. We previously showed that expression of Schistosoma mansoni MDR transporters increases in response to praziquantel (PZQ), the current drug of choice against schistosomiasis, and that reduced PZQ sensitivity correlates with higher levels of these parasite transporters. We have also shown that PZQ inhibits transport by SMDR2, a Pgp orthologue from S. mansoni, and that PZQ is a likely substrate of SMDR2. Here, we examine the physiological roles of SMDR2 and SmMRP1 (the S. mansoni orthologue of MRP1) in S. mansoni adults, using RNAi to knock down expression, and pharmacological agents to inhibit transporter function. We find that both types of treatments disrupt parasite egg deposition by worms in culture. Furthermore, administration of different MDR inhibitors to S. mansoni-infected mice results in a reduction in egg burden in host liver. These schistosome MDR transporters therefore appear to play essential roles in parasite egg production, and can be targeted genetically and pharmacologically. Since eggs are responsible for the major pathophysiological consequences of schistosomiasis, and since they are also the agents for transmission of the disease, these results suggest a potential strategy for reducing disease pathology and spread.


Subject(s)
Multidrug Resistance-Associated Proteins/antagonists & inhibitors , Multidrug Resistance-Associated Proteins/genetics , Schistosoma mansoni/drug effects , Schistosoma mansoni/physiology , ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors , Animals , Cyclosporine/pharmacology , Female , Gene Knockdown Techniques , Male , Mice , Multidrug Resistance-Associated Proteins/drug effects , Multidrug Resistance-Associated Proteins/metabolism , Ovum/drug effects , Parasite Load , Quinolines/pharmacology , RNA Interference , Schistosoma mansoni/genetics , Verapamil/pharmacology
9.
Mol Biochem Parasitol ; 173(1): 25-31, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20470831

ABSTRACT

The ATP-binding cassette (ABC) superfamily of proteins comprises several ATP-dependent efflux pumps involved in transport of toxins and xenobiotics from cells. These transporters are essential components of normal physiology, and a subset is associated with development of multidrug resistance. P-glycoprotein (Pgp) and the multidrug resistance-associated proteins (MRPs) represent two classes of these multidrug resistance (MDR) transporters. MRP1 is one type of mammalian MRP, which preferentially transports anionic compounds and compounds detoxified by cellular enzymes such as glutathione-S-transferase. It also transports signaling molecules, including immunomodulators. In schistosomes, both Pgp and MRP substrates localize to the excretory system, a potentially attractive target for new antischistosomals. We have previously shown that expression of schistosome Pgp (SMDR2) is altered in worms exposed to praziquantel (PZQ), the current drug of choice against schistosomiasis, and is expressed at higher levels in worms from isolates with reduced PZQ susceptibility. We have also shown that PZQ interacts directly with SMDR2. Here, we examine the relationship between PZQ and SmMRP1, a Schistosoma mansoni homolog of mammalian MRP1. SmMRP1 RNA is differentially expressed in adult males and females, and levels increase transiently following exposure of adult worms to sub-lethal concentrations of PZQ. A corresponding, though delayed, increase in anti-MRP1-immunoreactive protein also occurs following exposure to PZQ. PZQ-insensitive juvenile worms express higher levels of both SmMRP1 and SMDR2 RNA than mature adults, consistent with the hypothesis that increases in levels of schistosome multidrug transporters may be involved in development or maintenance of reduced susceptibility to PZQ.


Subject(s)
Anthelmintics/metabolism , Drug Resistance, Multiple , Helminth Proteins/metabolism , Multidrug Resistance-Associated Proteins/metabolism , Praziquantel/metabolism , Schistosoma mansoni/metabolism , Animals , Female , Gene Expression Regulation, Developmental/drug effects , Helminth Proteins/genetics , Male , Multidrug Resistance-Associated Proteins/genetics , Schistosoma mansoni/drug effects , Schistosoma mansoni/genetics , Schistosoma mansoni/growth & development , Schistosomiasis mansoni/parasitology
SELECTION OF CITATIONS
SEARCH DETAIL
...